LYCOS RETRIEVER 
Diclofenac: Patients
built 607 days ago
Diclofenac is an effective analgesic. A single dose administration of 50 mg had an NNT of 2.7 (2.4 to 3.1) for at least 50% pain relief over 4 to 6 hours compared with placebo in pain of moderate to severe intensity based on information from 738 patients.
Source:
NSAIDs, including Diclofenac Potassium, can cause serious skin adverse events such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. These serious events may occur without warning. Patients should be informed about the signs and symptoms of serious skin manifestations and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity.
Source:
The dosage of Generic for Diclofenac prescribed to each patient will vary. Always follow your physicians instructions and/or the directions on the prescription drug label. The following dosage information includes some common doses of Generic for Diclofenac. If your dose is different, do not follow any of the dosages described below unless your physician has approved.
Source:
Diclofenac ophthalmic is used to treat eye pain, redness, and swelling in patients who are recovering from cataract surgery (procedure to treat clouding of the lens in the eye). Diclofenac ophthalmic is ... used to temporarily relieve eye pain and sensitivity to light in patients who are recovering from corneal refractive surgery (surgery to improve vision). Diclofenac is in a class of medications called nonsteroidal anti-inflammatory medications. It works by stopping the production of certain natural substances that cause pain and swelling.
Source:
Diclofenac pharmacokinetics has been investigated in subjects with renal insufficiency. No differences in the pharmacokinetics of diclofenac have been detected in studies of patients with renal impairment. In patients with renal impairment (inulin clearance 60 to 90, 30 to 60, and < 30 mL/min; N = 6 in each group), AUC values and elimination rate were comparable to those in healthy subjects.
Source:
Because severe hepatotoxicity may develop without a prodrome of distinguishing symptoms, physicians should measure transaminases periodically in patients receiving long-term therapy with Diclofenac. The optimum times for making the first and subsequent transaminase measurements are not known. In the largest U.S. trial (open-label), which involved 3700 patients monitored first at 8 weeks and 1200 patients monitored again at 24 weeks, almost all meaningful elevations in transaminases were detected before patients became symptomatic. In 42 of the 51 patients in all trials who developed marked transaminase elevations, abnormal tests occurred during the first 2 months of therapy with Diclofenac. Based on this experience the first transaminase measurement should be made no later than 8 weeks after the start of Diclofenac treatment. As with other NSAIDs, if abnormal liver tests persist or worsen, if clinical signs and/or
Source:
MORE ABOUT
Patients